Definium Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
DFTX$34.64-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| (in thousands) | 2026 | 2025 |
| Cash flows from operating activities | ||
| Net loss | $(287,045) | $(133,357) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 27,546 | 14,495 |
| Change in fair value on directors' deferred share units ("DDSU") | 4,857 | 1,044 |
| Change in fair value of the 2022 USD Financing Warrants | 93,927 | 17,774 |
| Accretion of discount on investments, net | (3,009) | (281) |
| Amortization of debt issuance costs | 582 | — |
| Other non-cash adjustments | 104 | 14 |
| Changes in operating assets and liabilities: | ||
| Interest receivable | (3,310) | (1,998) |
| Prepaid and other current assets | 2,815 | 2,590 |
| Other non-current assets | (36) | 13 |
| Accounts payable | 3,930 | 6,103 |
| Accrued expenses | 11,348 | 5,035 |
| Other liabilities, long-term | (98) | (17) |
| Net cash used in operating activities | (148,389) | (88,585) |
| Cash flows from investing activities | ||
| Purchases of investments | (798,534) | (262,340) |
| Maturity of investments | 151,000 | 75,750 |
| Net cash used in investing activities | (647,534) | (186,590) |
| Cash flows from financing activities | ||
| Proceeds from equity offerings | 805,000 | — |
| Payment of equity offering costs | (46,270) | — |
| Proceeds from credit facility | — | 42,000 |
| Repayment of credit facility | — | (22,000) |
| Payment of credit facility issuance costs | — | (447) |
| Proceeds from exercise of pre-funded warrants | 9 | — |
| Proceeds from exercise of 2022 USD Financing Warrants | 15,184 | 1,004 |
| Proceeds from exercise of options | 4,573 | 432 |
| Proceeds from issuance of common shares under ESPP | 743 | 412 |
| Net cash provided by financing activities | 779,239 | 21,401 |
| Effect of exchange rate changes on cash | (3) | (8) |
| Net decrease in cash and cash equivalents | (16,687) | (253,782) |
| Cash and cash equivalents, beginning of period | 257,837 | 273,741 |
| Cash and cash equivalents, end of period | $241,150 | $19,959 |
| Supplemental Cash Flow Information | ||
| Cash paid for interest and final payment for credit facility | $3,144 | $4,646 |
| Supplemental Noncash Disclosures | ||
| Conversion of 2022 USD Financing Warrants to common shares upon exercise of warrants | 113,504 | 3,509 |
| Proceeds from exercise of 2022 USD Financing Warrants in prepaid and other current assets | — | 1,488 |
| Issuance of common shares upon conversion of term loan principal | 4,500 | 1,000 |
| Lease liabilities arising from obtaining right-of-use assets | 1,937 | 586 |
| Amortization of deferred financing costs | 123 | — |
| Withholding taxes payable on option exercises | — | 17 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.